Price Target Adjustment#
Truist Securities has lowered its price target for HCA Healthcare Inc. from $546 to $535, while still maintaining a Buy rating on the stock. Currently, HCA shares are trading at $442.80, reflecting a decline of 9.6% over the past week.
Financial Performance#
In its recent first-quarter results, HCA reported adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) that fell slightly short of Truist’s estimates and the broader market consensus. Over the last twelve months, HCA generated $15.57 billion in EBITDA, with a price-to-earnings (P/E) ratio of 15 and a price/earnings-to-growth (PEG) ratio of 0.48, indicating that the stock may be undervalued. The company has reaffirmed its financial guidance for 2026.
Challenges and Expectations#
HCA faced challenges during the quarter, including weaker respiratory patient volumes and adverse weather conditions that impacted overall patient numbers. However, these challenges were somewhat mitigated by improved supplemental Medicaid payments, which are now expected to be $200 million lower in year-over-year drag than previously anticipated. Health insurance exchange headwinds were reported at $150 million for the quarter, with full-year expectations remaining between $600 million and $900 million.
Market Outlook#
Despite the adjustments in price targets from various financial firms, including TD Cowen, Stephens, KeyBanc, and RBC Capital, all have maintained positive ratings on HCA's stock. Additionally, HCA Healthcare announced plans for its subsidiary, HCA Inc., to offer senior notes, with terms contingent on market conditions. These developments highlight both the current challenges HCA faces and its ongoing strategic financial maneuvers.